Ultime notizie per Benitec Biopharma (NASDAQ:BNTC) Azioni

Benitec Biopharma

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Benitec Biopharma Inc

Oppenheimer initiates coverage on Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Outperform rating and announces Price Target of $35.

News

Price Target

Initiation

Analyst Ratings

BNTC

Oppenheimer Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $35

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group raised JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) price target from $217 to $230. Evercore ISI Group analyst Glenn Schorr maintained an Outperform rating. JPMorgan shares closed at $222.29 on Friday. <a href="https://www.benzinga.com/quote/jpm/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital cut the price target for Nurix Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) from $27 to $26. RBC Capital analyst Gregory Renza maintained an Outperform rating. Nurix Therapeutics shares closed at $23.63 on Friday. <a href="https://www.benzinga.com/quote/nrix/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel raised the price target for V.F. Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) from $21 to $25. Stifel analyst Jim Duffy maintained a Buy rating. V.F. Corporation shares closed at $20.33 on Friday. <a href="https://www.benzinga.com/quote/vfc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush raised Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) price target from $25 to $45. Wedbush analyst David Chiaverini upgraded the stock from Underperform to Neutral. Affirm shares closed at $47.08 on Friday. <a href="https://www.benzinga.com/quote/afrm/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel cut Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) price target from $13 to $11. Stifel analyst Mark Kelley maintained a Hold rating. Snap shares closed at $11.13 on Friday. <a href="https://www.benzinga.com/quote/snap/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Evercore ISI Group raised Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) price target from $68 to $71. Evercore ISI Group analyst John Pancari maintained an Outperform rating. Wells Fargo shares closed at $60.99 on Friday. <a href="https://www.benzinga.com/quote/wfc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities raised the price target for Benitec Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) from $16 to $18. JMP Securities analyst Silvan Tuerkcan maintained a Market Outperform rating. Benitec Biopharma settled at $10.86 on Friday. <a href="https://www.benzinga.com/quote/bntc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised Boot Barn Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) price target from $147 to $179. Piper Sandler analyst Peter Keith maintained an Overweight rating. Boot Barn shares closed at $159.36 on Friday. <a href="https://www.benzinga.com/quote/boot/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised the price target for Fastenal Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) from $67 to $80. Baird analyst David Manthey maintained a Neutral rating. Fastenal shares closed at $76.82 on Friday. <a href="https://www.benzinga.com/quote/fast/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen cut ArcBest Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) price target from $131 to $114. TD Cowen analyst Jason Seidl downgraded the stock from Buy to Hold. ArcBest shares rose 1.4% to close at $105.95 on Friday. <a href="https://www.benzinga.com/quote/arcb/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying WFC stock? Here&#8217;s what analysts think:

Markets

Trading Ideas

AFRM

ARCB

BOOT

FAST

NRIX

SNAP

Wells Fargo To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Market Outperform and raises the price target from $16 to $18.

JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $18

<ul>
<li>-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing-</li>
<li>-Management plans to host a conference call on October 14 at 8:30 am EDT to discuss the interim results, details below-</li>
</ul>

Reported Saturday, Benitec Biopharma Reveals Data From Low-Dose BB-301 In Phase 1b/2a Study At World Muscle Society Congress

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock increased by 34.6% to $1.6 during Tuesday's regular session. The company's market cap stands at $2.9 million. </li>
<li>Sagimet Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) shares rose 17.68% to $3.26. The company's market cap stands at $104.9 million. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) shares rose 12.59% to $2.9. The market value of their outstanding shares is at $38.8 million. </li>
<li>Opthea (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPT#NASDAQ">OPT</a>) shares moved upwards by 12.53% to $4.58. The company's market cap stands at $704.8 million. </li>
<li>Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) stock rose 11.53% to $10.25. The company's market cap stands at $108.1 million. </li>
<li>BeyondSpring (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYSI#NASDAQ">BYSI</a>) shares rose 10.04% to $2.52. The market value of their outstanding shares is at $101.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares fell 57.4% to $0.25 during Tuesday's regular session. The company's market cap stands at $29.1 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock declined by 47.43% to $0.34. The market value of their outstanding shares is at $3.5 million. </li>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) stock fell 40.26% to $2.08. The market value of their outstanding shares is at $99.5 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) shares decreased by 18.4% to $5.5. The market value of their outstanding shares is at $19.3 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares declined by 17.53% to $0.32. The market value of their outstanding shares is at $14.8 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock fell 17.46% to $0.49. The company's market cap stands at $12.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADGM

APDN

BYSI

GRTS

MNPR

NUWE

SGMT

SNSE

STTK

XAIR

12 Health Care Stocks Moving In Tuesday's Intraday Session

JMP Securities analyst Silvan Tuerkcan reiterates Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Market Outperform and maintains $16 price target.

Reiteration

JMP Securities Reiterates Market Outperform on Benitec Biopharma, Maintains $16 Price Target

Earnings

Benitec Biopharma FY24 EPS $(5.51), Cash Runway Extended Through 2025

Biotech

General

Benitec Biopharma To Present Late Breaking Oral Abstract On BB-301 Phase 1b/2a Clinical Study At 29th Annual World Muscle Society Congress In October 2024

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Buy rating and announces Price Target of $17.

Guggenheim Initiates Coverage On Benitec Biopharma with Buy Rating, Announces Price Target of $17

Leerink Partners analyst Mani Foroohar initiates coverage on Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Outperform rating and announces Price Target of $13.

Leerink Partners Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $13

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Overweight rating and announces Price Target of $30.

Piper Sandler Initiates Coverage On Benitec Biopharma with Overweight Rating, Announces Price Target of $30

<h3>Gainers</h3>
<ul>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) stock moved upwards by 80.5% to $2.27 during Monday's regular session. The company's market cap stands at $36.6 million. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) stock rose 42.17% to $12.62. The market value of their outstanding shares is at $1.7 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) stock rose 27.79% to $4.23. The market value of their outstanding shares is at $264.6 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares moved upwards by 25.68% to $2.3. The market value of their outstanding shares is at $13.5 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) shares moved upwards by 24.01% to $2.43. The market value of their outstanding shares is at $134.0 million. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares increased by 21.74% to $8.4. The market value of their outstanding shares is at $7.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares declined by 40.1% to $0.84 during Monday's regular session. The company's market cap stands at $5.1 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock fell 22.03% to $2.69. The market value of their outstanding shares is at $2.3 million. The company's, Q2 earnings came out yesterday. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) stock declined by 19.66% to $0.07. The company's market cap stands at $4.6 million. </li>
<li>Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) shares decreased by 16.76% to $7.7. The market value of their outstanding shares is at $65.4 million. As per the press release, Q3 earnings came out today. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock declined by 16.12% to $1.54. The market value of their outstanding shares is at $6.9 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares declined by 15.78% to $27.82. The company's market cap stands at $2.4 billion. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CCLD

CHRO

FTRE

HSCS

MGNX

NVAX

OGEN

OMGA

RNAZ

TTNP

12 Health Care Stocks Moving In Monday's Intraday Session

WIIM

Benitec Biopharma shares are trading lower after the company reported worse-than-expected Q3 GAAP EPS results and a year-over-year decrease in Q3 revenue results.

Benitec Biopharma Q3 2024 Revenue $0 Down From $54,000 YoY

Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) reported quarterly losses of $(1.64) per share which missed the analyst consensus estimate of $(0.78) by 110.26 percent.

Earnings Misses

Benitec Biopharma Q3 2024 GAAP EPS $(1.64) Misses $(0.78) Estimate

Benitec Biopharma 13G Filing Shows Steven Oliveira Reported A 8.89% Passive Stake In The Co As Of April 22

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Market Outperform and raises the price target from $10 to $16.

JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $16

<h3>Gainers</h3>
<ul>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) shares moved upwards by 8.4% to $0.65. The market value of their outstanding shares is at $23.2 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares rose 7.78% to $0.4. The market value of their outstanding shares is at $4.1 million. </li>
<li>BIMI Intl Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) shares moved upwards by 7.46% to $1.44. The market value of their outstanding shares is at $20.1 million. </li>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) stock increased by 7.14% to $1.65. The company's market cap stands at $3.2 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock rose 6.06% to $1.05. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 18.2% to $3.2 during Thursday's after-market session. The company's market cap stands at $3.7 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock fell 11.17% to $0.37. The company's market cap stands at $3.3 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares declined by 9.39% to $0.22. The market value of their outstanding shares is at $4.3 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock declined by 8.76% to $0.04. The company's market cap stands at $4.4 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares decreased by 7.5% to $1.11. The market value of their outstanding shares is at $31.8 million. </li>
<li>Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) shares decreased by 6.16% to $6.4. The company's market cap stands at $16.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLR

BIMI

BIOR

BPTH

CYTH

ISPC

MBIO

PRTG

SINT

SXTC

VRPX

12 Health Care Stocks Moving In Thursday's After-Market Session

Thursday,&nbsp;Benitec Biopharma Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) released interim clinical data from the 90-day timepoint following the administration of BB-301 to the study&#8217;s first subject (Subject 1) treated in the BB-301 Phase 1b/2a study in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38310794/benitec-biopharma-reports-positive-interim-clinical-trial-data-for-first-opmd-subject-treated-with" rel="noreferrer noopener">Oculopharyngeal Muscular Dystrophy</a>&nbsp;(OPMD).
&#8220;To date, no clinical studies have systematically demonstrated a clinical improvement in OPMD patients across both objective and subjective measures of swallowing. We are, therefore, pleased to report positive interim clinical data from multiple radiographic measures as well as subject-reported outcome measures from the first subject treated with BB-301,&#8221; said Jerel Banks, Executive Chairman and Chief Executive Officer of Benitec.&nbsp;
During the OPMD Natural History Study, which represents the pre-dose observational period for each subject, Subject 1 experienced progressive worsening of dysphagia (difficulty swallowing) as demonstrated by the results of the videofluoroscopic swallowing studies (VFSS), the cold water timed drinking test.
At the 90-day timepoint following the administration of BB-301, Subject 1 demonstrated improvements in key videofluoroscopic assessments.
The results of many assessments completed at the 90-day timepoint demonstrated improvements over the initial measurements assessed at the subject&#8217;s first visit for the natural history observational study, which occurred more than 12 months before the 90-day assessment.
The most significant VFSS improvements at Day 90 were observed for swallowing tasks centered on evaluating pharyngeal constrictor muscle function and swallowing efficiency in consuming thin liquids, solid foods, and thick, non-solid foods.&nbsp;
So far, no severe side effects have been noted in the safety profile of BB-301. Two subjects experienced temporary Grade 2 (mild) Gastroesophageal Reflux Disease (GERD), which was treated with standard prescription medication.
OPMD is a rare progressive muscle-wasting disease caused by a poly(A)-binding protein nuclear 1 gene mutation. The disease is characterized by swallowing difficulties (dysphagia), limb weakness, and eyelid drooping (ptosis). Dysphagia worsens over time.
Concurrently, Benitec Biopharma announced a $40 million private investment in public equity (PIPE) financing from the sale of 5.7 million shares at $4.80/share and in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 2.58 million shares at a price per pre-funded warrant of $4.7999, to<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38310080/benitec-biopharma-announces-oversubscribed-private-placement-financing-of-40-0-million" rel="noreferrer noopener">&nbsp;certain institutional accredited investors.</a>
Price Action: BNTC shares are up 24% at $5.95 on the last check Thursday.
Illustration of Phrama lab worker created with MidJourney.

Equities

Health Care

Why Is Gene Therapy Developer Benitec Biopharma Stock Trading Higher On Thursday?

<h3>Gainers</h3>
<ul>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock moved upwards by 67.1% to $5.42 during Thursday's regular session. The market value of their outstanding shares is at $4.0 million. </li>
<li>Aileron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRN#NASDAQ">ALRN</a>) stock moved upwards by 53.88% to $6.54. The company's market cap stands at $111.0 million. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) stock moved upwards by 45.48% to $0.52. The company's market cap stands at $250.2 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 40.75% to $0.05. The company's market cap stands at $6.4 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares moved upwards by 33.19% to $0.28. The company's market cap stands at $2.5 million. </li>
<li>Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) shares moved upwards by 25.62% to $6.03. The market value of their outstanding shares is at $15.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) stock decreased by 27.0% to $0.51 during Thursday's regular session. The company's market cap stands at $38.4 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) stock declined by 26.35% to $5.34. The company's market cap stands at $29.2 million. </li>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) stock fell 25.12% to $3.13. The market value of their outstanding shares is at $29.9 million. </li>
<li>Genetic Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENE#NASDAQ">GENE</a>) stock fell 23.74% to $2.41. The market value of their outstanding shares is at $9.2 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) stock fell 20.39% to $0.29. The market value of their outstanding shares is at $13.8 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) stock decreased by 20.34% to $1.45. The market value of their outstanding shares is at $3.9 million. The company's, Q4 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALRN

GENE

INVO

NRXP

OTRK

12 Health Care Stocks Moving In Thursday's Intraday Session

Benitec Non-GAAP EPS of -$5.51

In a report released today, Silvan Tuerkcan from JMP Securities maintained a Buy rating on Benitec Biopharma (BNTC – Research Report), with a price...

Buy Rating Affirmed for Benitec Biopharma on Strong Clinical Progress and Solid Financials

Benitec Biopharma ($BNTC), a clinical-stage biotech firm, stands at the forefront of gene therapy, making notable strides in developing treatments ...

Benitec Biopharma (BNTC) Stock Surges on Potentially Groundbreaking OPMD Treatment

Benitec Biopharma Stock (BNTC) Surges on Potentially Groundbreaking OPMD Treatment

Benitec Biopharma's BB-301: Potential In OPMD But Still Too Early Stages

Analyst Silvan Tuerkcan of JMP Securities maintained a Buy rating on Benitec Biopharma (BNTC – Research Report), boosting the price target to $18.0...

Buy Rating Affirmed for Benitec Biopharma on Strong BB-301 Clinical Results and Positive Outlook

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Benitec Biopharma (BNTC – Research Report), with a price t...

Piper Sandler Remains a Buy on Benitec Biopharma (BNTC)

Benitec Biopharma ( ($BNTC) ) has provided an update. Benitec Biopharma Inc. announced promising interim results from its Phase 1b/2a trial for BB-...

Benitec Biopharma Reports Promising Results for BB-301 Trial

Benitec started at outperform by Oppenheimer on gene therapy potential

Benitec Biopharma: OPMD Program Continues To Advance With Catalysts

Press Releases

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

Benitec Biopharma to Participate in the Citizens JMP Life Science Conference

Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update

Management

Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study

Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar

Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society

Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update

Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society

Comments

Benitec Biopharma

Notizie

Ultime notizie per Benitec Biopharma (NASDAQ:BNTC) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO